NYSE:BMA News 22 January 2026

January 25, 2026, 9:19 PM EST. EZZ Life Science Holdings Limited (ASX:EZZ) saw its shares surge 33% in the past month but remains 19% lower over the year. The company's price-to-earnings (P/E) ratio stands at a modest 12.9x, well below the Australian average of 22x, suggesting potential undervaluation or lingering doubts about future earnings. Despite a 9.8% earnings drop last year, EZZ delivered a 363% EPS growth over three years, hinting at strong medium-term performance. The market expects around 23% growth next year, but some investors seem cautious, pushing the share price down. The stock's rebound reflects a risk-versus-reward scenario, with investors weighing steady gains against uncertainties about sustained profitability and market performance.